Corrigendum to “Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation” [Biochem. Biophys. Res. Commun. 323 (2004) 782–788]

Takeda Pharmaceuticals Company Limited (Takeda) wishes to comment on the above-referenced article. These authors are employees of Takeda and the research uponwhich the article is based is a part of Takeda s extensive and ongoing research and development effort. Takeda s highest goal is patient safety and to further this goal, it encourages the widespread publication of scientific and medical research to help the medical community better understand the medicines prescribed to patients. One of the most important internal requirements for publication is for any draft to undergo rigorous peer review by the researchers, scientists, and medical doctors at Takeda and its affiliates. Our peer-review process is intended, among other things, to assure that: